ReferenceID 577
Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
Oncogene
KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancers (NSCLCs). RAS proteins trigger multiple effector signalling pathways including the highly conserved RAF-MAPK pathway. CRAF, a dire
Relationship Network
Interactive first-hop connections across herbs, ingredients, formulas, targets, diseases, symptoms, syndromes, evidence, and monographs.
Click a node to open it in a new tab
Ingredient: 1Reference: 1Links: 1
Arranging relationship network...
Record Fields
Scalar fields from the final reference record.
- Reference Id
- 577
- Evidence Id
- 17167
- Core Evidence Id
- 17167
- Source Reference Id
- 1148
- Herb2 Reference Id
- HBREF001934
- Subject Paper Key
- HBIN042379_28414306
- Pubmed Id
- 28414306
- Doi
- 10.1038/onc.2017.93
- Paper Title
- Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
- Paper Abstract
- KRAS is one of the most frequently mutated oncogenes in human non-small cell lung cancers (NSCLCs). RAS proteins trigger multiple effector signalling pathways including the highly conserved RAF-MAPK pathway. CRAF, a direct RAS effector protein, is required for KRAS-mediated tumourigenesis. Thus, the molecular mechanisms driving the activation of CRAF are intensively studied. Prohibitin 1 (PHB1) is an evolutionarily conserved adaptor protein and interaction of CRAF with PHB1 at the plasma membrane is essential for CRAF activation. Here, we demonstrate that PHB1 is highly expressed in NSCLC patients and correlates with poor survival. Targeting of PHB1 with two chemical ligands (rocaglamide and fluorizoline) inhibits epidermal growth factor (EGF)/RAS-induced CRAF activation. Consistently, treatment with rocaglamide inhibited proliferation, migration and anchorage-independent growth of KRAS-mutated lung carcinoma cell lines. Surprisingly, rocaglamide treatment inhibited Ras-GTP loading in KRAS-mutated cells as well as in EGF-stimulated cells. Rocaglamide treatment further prevented the oncogenic growth of KRAS-driven lung cancer allografts and xenografts in mouse models. Our results suggest rocaglamide as a RAS inhibitor and that targeting plasma membrane-associated PHB1 with chemical ligands would be a viable therapeutic strategy to combat KRAS-mediated NSCLCs.
- Journal
- Oncogene
- Publish Year
- 2017
- Experiment Subject
- mouse
- Experiment Type
- Animal Experiment
- Phenotype Related
- Non-small Cell Lung Cancers
- Paper Title Cn
- Paper Title En
- Targeting prohibitins with chemical ligands inhibits KRAS-mediated lung tumours
- Bilingual Status
- semi_complete